Xingyu Wang

Ms. Xingyu Wang


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
XWXingyu Wang
Xingyu Wang
ZRZhouting Rong
Zhouting Rong
FXFeng Xue
Feng Xue
Alzheimer’s Disease (AD), the most common form of dementia, is pathologically defined by extracellular beta-amyloid (Aβ) plaques and intraneuronal neurofibrillary tangles (NFTs), accompanied by chronic neuroinflammation. Recent advances in single-cell RNA sequencing (scRNA-seq/snRNA-seq) and spatial transcriptomics have provided unprecedented resolution for unraveling the cellular and molecular landscape of neuroinflammation in AD. While scRNA-seq enables high-throughput profiling of cellular heterogeneity across brain regions, spatial transcriptomics preserves tissue architecture to map cell-type-specific gene expression within its anatomical context. This review synthesizes the neuroinflammatory mechanisms of AD, outlines the technical evolution and comparative capabilities of single-cell and spatial omics platforms, including resolution, throughput, and compatibility with multiple sample types, and critically evaluates findings from studies in both animal models and human brain tissues. These approaches have revealed state-specific transitions in microglia and astrocytes, including shifts in transcriptional programs, metabolic reprogramming, and pro-inflammatory polarization across disease stages. Notably, spatial transcriptomic analyses demonstrate pronounced regional heterogeneity: periplaque microenvironments exhibit distinct immune-cell compositions and gene expression signatures. Collectively, these omics technologies are redefining the cellular basis of AD progression and hold the potential to impact the discovery of early diagnostic biomarkers and precision therapeutic targets.

2 July 2026 in Cells
Verified
Journal Article
Open access
PDF file
LPLi xiao Pu
Li xiao Pu
XWXingyu Wang
Xingyu Wang
JDJiaxing D ou
Jiaxing D ou
JWJiahui Wang
Jiahui Wang
FXFeng Xue
Feng Xue
Alzheimer’s Disease (AD) is now understood as a biologically diverse condition, with amyloid and tau pathology evolving within dynamic neuroimmune networks. This challenges the traditional view that AD-related inflammation can be broadly suppressed therapeutically. We review evidence showing that neuroinflammation in AD is stage-dependent, cell-state-specific, spatially organized, and functionally complex. Microglia and astrocytes can aid in plaque containment, debris clearance, synaptic balance, metabolic adaptation, and tissue repair, but may also exacerbate injury through type-I interferon, inflammasome, complement, tumor necrosis factor, and lipid pathways. Many failed anti-inflammatory trials likely stem from mismatches in targets, timing, spatial considerations, pathway redundancy, and biomarker selection, rather than invalidating neuroinflammation as a therapeutic target. Recent single-cell and spatial transcriptomic, proteomic, metabolomic, and network-medicine studies offer a framework for precision intervention by identifying inflammatory endotypes, anatomical niches, and pathway modules. We propose the Stage–State–Space Neuroimmune Reprogramming Model (S3-NRM), aligning AD immunotherapy with disease stage, glial/endotype state, and spatial inflammatory niche, guided by fluid, imaging, and omics biomarkers. Future therapies should selectively suppress harmful immune responses while preserving beneficial glial functions.

28 April 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
LPLi xiao Pu
Li xiao Pu
XWXingyu Wang
Xingyu Wang
FXFeng Xue
Feng Xue
Alzheimer’s Disease (AD) is now understood as a biologically diverse condition, with amyloid and tau pathology evolving within dynamic neuroimmune networks. This challenges the traditional view that AD-related inflammation can be broadly suppressed therapeutically. We review evidence showing that neuroinflammation in AD is stage-dependent, cell-state-specific, spatially organized, and functionally complex. Microglia and astrocytes can aid in plaque containment, debris clearance, synaptic balance, metabolic adaptation, and tissue repair, but may also exacerbate injury through type-I interferon, inflammasome, complement, tumor necrosis factor, and lipid pathways. Many failed anti-inflammatory trials likely stem from mismatches in targets, timing, spatial considerations, pathway redundancy, and biomarker selection, rather than invalidating neuroinflammation as a therapeutic target. Recent single-cell and spatial transcriptomic, proteomic, metabolomic, and network-medicine studies offer a framework for precision intervention by identifying inflammatory endotypes, anatomical niches, and pathway modules. We propose the Stage–State–Space Neuroimmune Reprogramming Model (S3-NRM), aligning AD immunotherapy with disease stage, glial/endotype state, and spatial inflammatory niche, guided by fluid, imaging, and omics biomarkers. Future therapies should selectively suppress harmful immune responses while preserving beneficial glial functions.

Verified
Journal Article
Open access
PDF file
SCShihan Chen
Shihan Chen
XWXingyu Wang
Xingyu Wang
JDJiaxing D ou
Jiaxing D ou
JWJiahui Wang
Jiahui Wang
LPLi xiao Pu
Li xiao Pu
FXFeng Xue
Feng Xue
Research on gut microbiota in Alzheimer’s disease (AD) has progressed from observational correlation studies toward investigation of causal relationships in preclinical models. Human observational studies have reported associations between alterations in gut microbiota and the entire spectrum of AD, from the preclinical stage to dementia, and are associated with Amyloid-beta (Aβ) deposition, phosphorylated Tau (p-tau) positivity, dysregulation of bile acid and short-chain fatty acid (SCFA) metabolism, as well as impaired intestinal barrier function. The strongest causal evidence currently derives from germ-free or antibiotic-treated animal models, fecal microbiota transplantation (FMT) between healthy controls and AD patients, and colonization by specific bacterial strains or metabolites—interventions that have been shown to modulate Aβ load, tau phosphorylation, microglial activation, synaptic pruning, and cognitive behavior in animal models. Mechanistically, the gut–brain axis in AD has been proposed to integrate four interconnected pathways, with the strength of evidence and the extent of human validation varying considerably across them: (1) reduced production of SCFA-producing bacteria accompanied by upregulation of pro-inflammatory pathways; (2) disruption of intestinal epithelial tight junctions, allowing lipopolysaccharide (LPS) and bacterial toxins to enter the systemic circulation; (3) reprogramming of peripheral and central innate immune systems, leading to hyperactivation of microglia and complement-mediated synaptic clearance; and (4) global rearrangement of microbial metabolite networks (including SCFAs, bile acids, tryptophan metabolites, and LPS), has been proposed to collectively regulate Aβ homeostasis, tau pathology, microglial activation, and blood–brain barrier (BBB) integrity. Clinically, the evidence base remains uneven: probiotics have been associated with some improvements in some inflammatory markers and cognitive measures in small randomized controlled trials (RCTs); FMT has been reported in case studies in human AD; modified ketogenic diets have been associated with cerebrospinal fluid (CSF) biomarkers; and molecules such as GV-971 (Sodium Oligomannate) provide proof-of-concept for microbiota-targeted strategies, though independent validation is needed. Overall, gut microbiota research in AD has advanced considerably, with animal and human studies suggesting that dysbiosis may contribute to AD pathology through immune, metabolic, and barrier-related pathways, although clinical intervention evidence remains preliminary and requires further validation.

21 April 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
XWXingyu Wang
Xingyu Wang
ZRZhouting Rong
Zhouting Rong
FXFeng Xue
Feng Xue
Alzheimer’s Disease (AD), the most prevalent form of dementia, is pathologically defined by extracellular beta-amyloid (Aβ) plaques and intraneuronal neurofibrillary tangles (NFTs), accompanied by chronic neuroinflammation. Recent advances in single-cell RNA sequencing (scRNA-seq/snRNA-seq) and spatial transcriptomics have provided unprecedented resolution for dissecting the cellular and molecular landscape of neuroinflammation in AD. While scRNA-seq enables high-throughput profiling of cellular heterogeneity across brain regions, spatial transcriptomics preserves tissue architecture to map cell-type-specific gene expression within anatomical contexts. This review synthesizes the neuroinflammatory mechanisms of AD, outlines the technical evolution and comparative capabilities of single-cell and spatial omics platforms, including resolution, throughput, and compatibility with multiple sample types, and critically evaluates findings from studies in both animal models and human brain tissues. These approaches have revealed state-specific transformations in microglia and astrocytes, including shifts in transcriptional programs, metabolic reprogramming, and pro-inflammatory polarization across disease stages. Notably, spatial transcriptomic analyses demonstrate pronounced regional heterogeneity: periplaque microenvironments exhibit distinct immune cell compositions and gene expression signatures. Collectively, these omics technologies are redefining the cellular basis of AD progression and hold transformative potential for the discovery of early diagnostic biomarkers and precision therapeutic targets.

30 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
SCShihan Chen
Shihan Chen
XWXingyu Wang
Xingyu Wang
JDJiaxing D ou
Jiaxing D ou
JWJiahui Wang
Jiahui Wang
LPLi xiao Pu
Li xiao Pu
FXFeng Xue
Feng Xue
Research on gut microbiota in Alzheimer’s disease (AD) has progressed from observational correlations to the validation of causal relationships. Human studies consistently demonstrate that alterations in gut microbiota span the entire spectrum of AD, from the preclinical stage to dementia, and are associated with Amyloid-beta (Aβ) deposition, phosphorylated Tau (p-tau) positivity, dysregulation of bile acid and short-chain fatty acid (SCFA) metabolism, as well as impaired intestinal barrier function. The strongest causal evidence comes from germ-free/antibiotic-treated animal models, fecal microbiota transplantation (FMT) between healthy controls and AD patients, and colonization by specific pathogenic bacteria or metabolites—interventions that directly modulate Aβ load, tau phosphorylation, microglial activation, synaptic pruning, and cognitive behavior. Mechanistically, the gut-brain axis in AD integrates four interconnected pathways: (1) reduced production of SCFA-producing acidogenic bacteria accompanied by upregulation of pro-inflammatory pathways; (2) disruption of intestinal epithelial tight junctions, allowing lipopolysaccharide (LPS) and bacterial toxins to enter the systemic circulation; (3) reprogramming of peripheral and central innate immune systems, leading to hyperactivation of microglia and complement-mediated synaptic clearance; and (4) global rearrangement of microbial metabolite networks (including SCFAs, bile acids, tryptophan-ketouric acid derivatives, and LPS), collectively regulating Aβ homeostasis, tau pathology, microglial activation, and blood-brain barrier (BBB) integrity. Clinically, evidence levels remain uneven: probiotics/bifidobiotics have demonstrated improvements in inflammation and certain cognitive domains in small randomized controlled trials (RCTs); FMT has only been supported by case reports in human AD; modified ketogenic diets have shown correlations with cerebrospinal fluid (CSF) biomarkers; molecules such as GV-971 provide proof-of-concept for microbiota-targeted strategies but require broader independent validation. Overall, gut microbiota research in AD has entered a new phase, with animal and human studies indicating that dysbiosis can drive AD pathology through multiple pathways including immune, metabolic, and barrier dysfunction, though clinical intervention evidence remains inconsistent and requires further validation.